← Pacira BioSciences overview

Pacira BioSciences vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pacira BioSciences, Inc. (PCRX)

Q3 2026
▲2

Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth

  • Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.

    The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.

  • EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.

    It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.

  • Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.

    It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.

September 2026
▲2

Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth

  • Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.

    The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.

  • EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.

    It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.

  • Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.

    It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.

Latest
▲2

Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth

  • Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.

    The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.

  • EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.

    It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.

  • Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.

    It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.